Jan Bauer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jan Bauer has a total of 963 co-authors. Here are the top co-authors by number of shared publications:
- Hans Lassmann
Department of Neuroimmunology, Center for Brain Research Medical University of Vienna Vienna Austria
60 shared publications - Christian G. Bien
Department of Epileptology, Krankenhaus Mara, Bethel Epilepsy Center, Medical School OWL, Bielefeld University, Germany
25 shared publications - Roland Liblau
Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), University of Toulouse, CNRS, INSERM, UPS, 31024 Toulouse, France
22 shared publications Jon D. Laman
University Groningen, University Medical Center, Department of Neuroscience, Groningen, The Netherlands
19 shared publications- Bert A. 'T Hart
Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, The Netherlands
17 shared publications - Erwin L. A. Blezer
Image Sciences Institute, University Medical Center Utrecht, Utrecht, The Netherlands
17 shared publications
Latest Publications
- Open Access
- 14 September 2026
- Published by Springer Nature in Research Square
Universal seropositivity, markers of recurrent reactivation, and a convergent T-cell response implicate cytomegalovirus in Susac syndrome
Susac syndrome (SuS) is a rare brain, retina, and inner ear endotheliopathy, in which CD8⁺ T cells are thought to target the microvascular endothelium. We applied unbiased, HLA-restricted antigen-specificity annotation of T-cell receptor beta-chain repertoires, followed by targeted serology, virology, and single-cell profiling, to a multicenter German cohort of 72 patients with definite SuS. Repertoires showed increased clonality and convergent expansion of CMV-specific clusters positively associated with age, alongside expansion of adaptive NKG2C⁺ natural killer cells. T cells converged on the immediate-early-1 epitope CRVLCCYVL in carriers of HLA-C*07:02, an allele nominally enriched in this cohort, together indicating recurrent antigen exposure. Every tested patient with SuS was CMV IgG-positive (70 of 70), and 37% of patients were CMV IgM-positive or DNAemic at one or more time points. This was confirmed at diagnosis in an untreated Belgian validation cohort with 100% CMV IgG-positivity (13 of 13) and 31% IgM-positivity. Serum DNAemia, but not IgM, coincided with disease activity. Single-cell profiling of a patient with SuS, hospitalized for CMV disease eleven months before disease onset, showed the same antigenic focus alongside a CMV reactivation phenotype resembling that of allogeneic transplant recipients. These findings implicate recurrent CMV reactivation in the pathogenesis of SuS, support further prospective evaluation of diagnostic CMV testing, and provide a foundation for assessment of treatment strategies combining antiviral and immunomodulatory effects.
- 14 September 2026
- Published by Springer Nature in Research Square
Open AccessUniversal seropositivity, markers of recurrent reactivation, and a convergent T-cell response implicate cytomegalovirus in Susac syndrome
Susac syndrome (SuS) is a rare brain, retina, and inner ear endotheliopathy, in which CD8⁺ T cells are thought to target the microvascular endothelium. We applied unbiased, HLA-restricted antigen-specificity annotation of T-cell receptor beta-chain repertoires, followed by targeted serology, virology, and single-cell profiling, to a multicenter German cohort of 72 patients with definite SuS. Repertoires showed increased clonality and convergent expansion of CMV-specific clusters positively associated with age, alongside expansion of adaptive NKG2C⁺ natural killer cells. T cells converged on the immediate-early-1 epitope CRVLCCYVL in carriers of HLA-C*07:02, an allele nominally enriched in this cohort, together indicating recurrent antigen exposure. Every tested patient with SuS was CMV IgG-positive (70 of 70), and 37% of patients were CMV IgM-positive or DNAemic at one or more time points. This was confirmed at diagnosis in an untreated Belgian validation cohort with 100% CMV IgG-positivity (13 of 13) and 31% IgM-positivity. Serum DNAemia, but not IgM, coincided with disease activity. Single-cell profiling of a patient with SuS, hospitalized for CMV disease eleven months before disease onset, showed the same antigenic focus alongside a CMV reactivation phenotype resembling that of allogeneic transplant recipients. These findings implicate recurrent CMV reactivation in the pathogenesis of SuS, support further prospective evaluation of diagnostic CMV testing, and provide a foundation for assessment of treatment strategies combining antiviral and immunomodulatory effects.
- Open Access
- 26 July 2026
- Published by Wiley in Brain Pathology
- p. e70127
The immunological landscape of the area postrema in neuromyelitis optica spectrum disorders
Patients suffering from aquaporin‐4 antibody‐positive neuromyelitis spectrum disorder may present with radically different types of lesions in the central nervous system. They may show large tissue destructive lesions, as typically seen in medulla, spinal cord, and optic nerves, and lesions with much better tissue preservation, as seen in the area postrema. The causes for the resilience of the area postrema to the action of aquaporin 4‐antibodies are currently unclear. We performed detailed immunohistochemical analysis combined with spatial transcriptomics and functional annotation clustering, and identified key differences in the immunological landscape between the area postrema and the medulla. In the area postrema, only few chemokines were upregulated in response to AQP4 antibodies. Therefore, the immune response was dominated by local microglial/macrophages which displayed a low grade of microgliosis and an overall low level of activation. Il‐1β expression was below our cut‐off for detection. This was in marked contrast to lesions in the medulla, which were characterized by the expression of many chemokines underlying the recruitment of macrophages and neutrophils from the periphery to this site, and by Il‐1β expression. Aldehyde dehydrogenase 1 family member A2 (Aldh1a2), the key molecule for retinoic acid synthesis, was strongly expressed in the area postrema, but not in the medulla. Because retinoic acid can prevent the activation of astrocytes and microglia, can reduce the production of cytokine/chemokine transcripts, can alleviate the expression of IL‐1β, and can promote an M1‐ to M2‐transition in macrophages, our data implicate a protective role of retinoic acid at this site.
- 26 July 2026
- Published by Wiley in Brain Pathology
- p. e70127
Open AccessThe immunological landscape of the area postrema in neuromyelitis optica spectrum disorders
Patients suffering from aquaporin‐4 antibody‐positive neuromyelitis spectrum disorder may present with radically different types of lesions in the central nervous system. They may show large tissue destructive lesions, as typically seen in medulla, spinal cord, and optic nerves, and lesions with much better tissue preservation, as seen in the area postrema. The causes for the resilience of the area postrema to the action of aquaporin 4‐antibodies are currently unclear. We performed detailed immunohistochemical analysis combined with spatial transcriptomics and functional annotation clustering, and identified key differences in the immunological landscape between the area postrema and the medulla. In the area postrema, only few chemokines were upregulated in response to AQP4 antibodies. Therefore, the immune response was dominated by local microglial/macrophages which displayed a low grade of microgliosis and an overall low level of activation. Il‐1β expression was below our cut‐off for detection. This was in marked contrast to lesions in the medulla, which were characterized by the expression of many chemokines underlying the recruitment of macrophages and neutrophils from the periphery to this site, and by Il‐1β expression. Aldehyde dehydrogenase 1 family member A2 (Aldh1a2), the key molecule for retinoic acid synthesis, was strongly expressed in the area postrema, but not in the medulla. Because retinoic acid can prevent the activation of astrocytes and microglia, can reduce the production of cytokine/chemokine transcripts, can alleviate the expression of IL‐1β, and can promote an M1‐ to M2‐transition in macrophages, our data implicate a protective role of retinoic acid at this site.
- Open Access
- 25 March 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (13)
Immune cell profiling reveals expanded stem cell–like memory T cells in anti-GAD65-associated neurological syndromes
The immunopathogenesis of autoimmune neurological syndromes (AINS) with antibodies against the 65 kDa isoform of glutamic acid decarboxylase (anti-GAD65 AINS) remains poorly understood. To elucidate underlying disease mechanisms and identify relevant cell populations, we performed single-cell RNA and immune repertoire sequencing of cerebrospinal fluid (CSF) and peripheral blood mononuclear cells (PBMCs) of eight anti-GAD65 AINS individuals compared to eight noninflammatory controls. In addition, PBMCs from 19 anti-GAD65 AINS individuals and 20 healthy controls were analyzed by multidimensional flow cytometry, and brain tissue specimens from four anti-GAD65 AINS individuals were examined histologically. We detected higher frequencies of stem cell–like memory T cells (TSCM) within the PBMCs and a marked enrichment and clonal expansion of activated CD4 + TSCM in the CSF of anti-GAD65 AINS individuals. Expanded T cells exhibited increased expression of proinflammatory genes. Histological analyses confirmed intraparenchymal CD8 + TSCM in three of four anti-GAD65 AINS individuals and rare meningeal/intraparenchymal CD4 + TSCM in one person. Although CSF B cell receptors (BCRs) displayed little to no clonal expansion, recombinant expression of 40 CSF BCRs revealed that 25% were GAD65-reactive with increased somatic hypermutations compared to non-GAD65-reactive BCRs. These findings further support the concept of an antigen-specific intrathecal immune response. In summary, we characterize the immune landscape of anti-GAD65 AINS at single-cell resolution and identify clonally expanded TSCM with cytotoxic properties as a hallmark of this disease.
- 25 March 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (13)
Open AccessImmune cell profiling reveals expanded stem cell–like memory T cells in anti-GAD65-associated neurological syndromes
The immunopathogenesis of autoimmune neurological syndromes (AINS) with antibodies against the 65 kDa isoform of glutamic acid decarboxylase (anti-GAD65 AINS) remains poorly understood. To elucidate underlying disease mechanisms and identify relevant cell populations, we performed single-cell RNA and immune repertoire sequencing of cerebrospinal fluid (CSF) and peripheral blood mononuclear cells (PBMCs) of eight anti-GAD65 AINS individuals compared to eight noninflammatory controls. In addition, PBMCs from 19 anti-GAD65 AINS individuals and 20 healthy controls were analyzed by multidimensional flow cytometry, and brain tissue specimens from four anti-GAD65 AINS individuals were examined histologically. We detected higher frequencies of stem cell–like memory T cells (TSCM) within the PBMCs and a marked enrichment and clonal expansion of activated CD4 + TSCM in the CSF of anti-GAD65 AINS individuals. Expanded T cells exhibited increased expression of proinflammatory genes. Histological analyses confirmed intraparenchymal CD8 + TSCM in three of four anti-GAD65 AINS individuals and rare meningeal/intraparenchymal CD4 + TSCM in one person. Although CSF B cell receptors (BCRs) displayed little to no clonal expansion, recombinant expression of 40 CSF BCRs revealed that 25% were GAD65-reactive with increased somatic hypermutations compared to non-GAD65-reactive BCRs. These findings further support the concept of an antigen-specific intrathecal immune response. In summary, we characterize the immune landscape of anti-GAD65 AINS at single-cell resolution and identify clonally expanded TSCM with cytotoxic properties as a hallmark of this disease.
- Open Access
- 12 June 2025
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 22 (1) , 1-15
The dynamics of brain T cell populations during the course of rasmussen encephalitis: from expansion to exhaustion
Rasmussen Encephalitis (RE) is a chronic, unilateral epileptic disorder mostly found in children. Neuropathologically, it is characterized by T lymphocyte infiltration targeting neurons and leading to microglia activation, astrogliosis, and cortical degeneration. Within a patient’s brain, distinct pathological stages are found that offer a unique opportunity to study T cell dynamics in situ. Using quantitative multiplex fluorescence imaging, we analyzed CD103+ and CD69+ Tissue-resident memory T cells (TRM) across different disease stages. This analysis revealed that TRM were more abundant in the parenchyma than in the perivascular space, suggesting that their differentiation occurs locally after antigen encounter. Further, part of the TRM expressed Granzyme-B (GrB) and frequently were attached to neurons, suggesting that they are actively involved in neuronal destruction. While TRM showed a stage-dependent increase in older lesions, the proportions of these cells did not correlate with disease duration, indicating that their accumulation may be more dependent on the local environment in the lesion than on the length of the disease. In addition, we found that T cells using the γδ T cell receptor comprised up to 66%. Like CD8+ T cells, the γδ T cells could develop a TRM phenotype and, while expressing GrB+ granules, they were seen attached to neurons, suggesting that they are involved in neuronal destruction. Finally, analysis of exhaustion- and TRM-associated immune checkpoint control markers PD-1 and LAG-3 revealed a significant stage-dependent increase in PD-1 expression in the oldest lesions. In contrast, LAG-3 expression did not show any stage-specific pattern, pointing towards a distinct regulatory mechanism. The study demonstrates a dynamic and one-way T cell response throughout the course of RE at a given spot in the CNS: from the establishment of T cell residence after entry into the CNS, the killing of neurons, and eventually T cell exhaustion. It further suggests an important role of γδ T-cells in the propagation of disease and lesions.
- 12 June 2025
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 22 (1) , 1-15
Open AccessThe dynamics of brain T cell populations during the course of rasmussen encephalitis: from expansion to exhaustion
Rasmussen Encephalitis (RE) is a chronic, unilateral epileptic disorder mostly found in children. Neuropathologically, it is characterized by T lymphocyte infiltration targeting neurons and leading to microglia activation, astrogliosis, and cortical degeneration. Within a patient’s brain, distinct pathological stages are found that offer a unique opportunity to study T cell dynamics in situ. Using quantitative multiplex fluorescence imaging, we analyzed CD103+ and CD69+ Tissue-resident memory T cells (TRM) across different disease stages. This analysis revealed that TRM were more abundant in the parenchyma than in the perivascular space, suggesting that their differentiation occurs locally after antigen encounter. Further, part of the TRM expressed Granzyme-B (GrB) and frequently were attached to neurons, suggesting that they are actively involved in neuronal destruction. While TRM showed a stage-dependent increase in older lesions, the proportions of these cells did not correlate with disease duration, indicating that their accumulation may be more dependent on the local environment in the lesion than on the length of the disease. In addition, we found that T cells using the γδ T cell receptor comprised up to 66%. Like CD8+ T cells, the γδ T cells could develop a TRM phenotype and, while expressing GrB+ granules, they were seen attached to neurons, suggesting that they are involved in neuronal destruction. Finally, analysis of exhaustion- and TRM-associated immune checkpoint control markers PD-1 and LAG-3 revealed a significant stage-dependent increase in PD-1 expression in the oldest lesions. In contrast, LAG-3 expression did not show any stage-specific pattern, pointing towards a distinct regulatory mechanism. The study demonstrates a dynamic and one-way T cell response throughout the course of RE at a given spot in the CNS: from the establishment of T cell residence after entry into the CNS, the killing of neurons, and eventually T cell exhaustion. It further suggests an important role of γδ T-cells in the propagation of disease and lesions.
- Top Cited Papers
- 2 May 2025
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 21 (6) , 312-326
Autoimmune encephalitis-associated epilepsy
Autoimmune encephalitis (AE), defined by clinical criteria and its frequent association with neural autoantibodies, often manifests with seizures, which usually stop with immunotherapy. However, a subset of encephalitic conditions present with recurrent seizures that are resistant to immunotherapy. Three primary neurological constellations that fall within this subset are discussed in this Perspective: temporal lobe epilepsy with antibodies against glutamic acid decarboxylase, epilepsy in the context of high-risk paraneoplastic antibodies, and epilepsy following adequately treated surface antibody-mediated AE. These entities all share a common mechanism of structural injury and potentially epileptogenic focal neural loss, often induced by cytotoxic T cells. Recently, we have proposed conceptualizing these conditions under the term autoimmune encephalitis-associated epilepsy (AEAE). Here, we discuss the new concept of AEAE as an emerging field of study. We consider the clinical characteristics of patients who should be investigated for AEAE and highlight the need for judicious use of traditional epilepsy therapeutics alongside immunotherapeutic considerations that are of uncertain and incomplete efficacy for this group of disorders. Last, we discuss future efforts needed to diagnose individuals before structural epileptogenesis has superseded inflammation and to develop improved therapeutics that target the specific immunological or functional disturbances in this entity.
- 2 May 2025
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 21 (6) , 312-326
Top Cited PapersAutoimmune encephalitis-associated epilepsy
Autoimmune encephalitis (AE), defined by clinical criteria and its frequent association with neural autoantibodies, often manifests with seizures, which usually stop with immunotherapy. However, a subset of encephalitic conditions present with recurrent seizures that are resistant to immunotherapy. Three primary neurological constellations that fall within this subset are discussed in this Perspective: temporal lobe epilepsy with antibodies against glutamic acid decarboxylase, epilepsy in the context of high-risk paraneoplastic antibodies, and epilepsy following adequately treated surface antibody-mediated AE. These entities all share a common mechanism of structural injury and potentially epileptogenic focal neural loss, often induced by cytotoxic T cells. Recently, we have proposed conceptualizing these conditions under the term autoimmune encephalitis-associated epilepsy (AEAE). Here, we discuss the new concept of AEAE as an emerging field of study. We consider the clinical characteristics of patients who should be investigated for AEAE and highlight the need for judicious use of traditional epilepsy therapeutics alongside immunotherapeutic considerations that are of uncertain and incomplete efficacy for this group of disorders. Last, we discuss future efforts needed to diagnose individuals before structural epileptogenesis has superseded inflammation and to develop improved therapeutics that target the specific immunological or functional disturbances in this entity.
- Open Access
- 17 March 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 148 (9) , 3170-3183
Activated αβ T and reduced mucosa-associated invariant T cells in LGI1- and CASPR2-encephalitis
Anti-leucine-rich glioma inactivated-1 (LGI1) and anti-contactin-associated-protein-2 (CASPR2) autoimmune encephalitis (AIE) are common and characterized by pathogenic antibodies targeting neuronal autoantigens. However, the drivers of the antibody-secreting cells and involvement of T cells remain unresolved. We performed single-cell RNA sequencing of fresh CSF and parallel blood samples of 15 patients with LGI1-AIE (n = 9) and CASPR2-AIE (n = 6) compared with control patients [multiple sclerosis (n = 15) and idiopathic intracranial hypertension (n = 18)]. We validated our observations in independent cohorts using flow cytometry of CSF and blood. We confirmed autoantibody specificity using recombinant human monoclonal antibodies. In comparison to idiopathic intracranial hypertension and multiple sclerosis controls, we observed clonal CSF-specific antibody-secreting cell expansion in LGI1/CASPR2-AIE despite mostly normal CSF findings. Antibody-secreting cells were dominantly plasmablasts and transcribed IgG4 and IgG1/2 heavy chains. Expanded clones showed signs of affinity maturation and bound the respective neuronal autoantigen. Within CD4 and CD8 T-cell clusters, CD4 and CD8 central memory T cells were activated, clonally restricted and expanded. T-cell clones were often shared between CSF and blood. We also observed a shift of natural killer cells and loss of mucosa-associated invariant T (MAIT) cells in the CSF of LGI1-AIE and the blood of LGI1- and CASPR2-AIE compared with idiopathic intracranial hypertension and multiple sclerosis controls. MAIT-like T cells were detected in autopsied brains of LGI1- and CASPR2-AIE patients, and mice lacking MAIT cells displayed an increased antibody seroconversion and higher titres following active LGI1/CASPR2 immunization. Our data: (i) confirm the intrathecal antigen-specific plasma cell expansion in LGI1- and CASPR2-AIE in a large cohort of untreated AIE patients; (ii) suggest that activated and expanded central memory CD4 and CD8 T cells in the CSF participate in disease pathogenesis; and (iii) implicate invariant T-cell receptor-expressing lymphocytes in the brain, CSF and blood in disease pathogenesis.
- 17 March 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 148 (9) , 3170-3183
Open AccessActivated αβ T and reduced mucosa-associated invariant T cells in LGI1- and CASPR2-encephalitis
Anti-leucine-rich glioma inactivated-1 (LGI1) and anti-contactin-associated-protein-2 (CASPR2) autoimmune encephalitis (AIE) are common and characterized by pathogenic antibodies targeting neuronal autoantigens. However, the drivers of the antibody-secreting cells and involvement of T cells remain unresolved. We performed single-cell RNA sequencing of fresh CSF and parallel blood samples of 15 patients with LGI1-AIE (n = 9) and CASPR2-AIE (n = 6) compared with control patients [multiple sclerosis (n = 15) and idiopathic intracranial hypertension (n = 18)]. We validated our observations in independent cohorts using flow cytometry of CSF and blood. We confirmed autoantibody specificity using recombinant human monoclonal antibodies. In comparison to idiopathic intracranial hypertension and multiple sclerosis controls, we observed clonal CSF-specific antibody-secreting cell expansion in LGI1/CASPR2-AIE despite mostly normal CSF findings. Antibody-secreting cells were dominantly plasmablasts and transcribed IgG4 and IgG1/2 heavy chains. Expanded clones showed signs of affinity maturation and bound the respective neuronal autoantigen. Within CD4 and CD8 T-cell clusters, CD4 and CD8 central memory T cells were activated, clonally restricted and expanded. T-cell clones were often shared between CSF and blood. We also observed a shift of natural killer cells and loss of mucosa-associated invariant T (MAIT) cells in the CSF of LGI1-AIE and the blood of LGI1- and CASPR2-AIE compared with idiopathic intracranial hypertension and multiple sclerosis controls. MAIT-like T cells were detected in autopsied brains of LGI1- and CASPR2-AIE patients, and mice lacking MAIT cells displayed an increased antibody seroconversion and higher titres following active LGI1/CASPR2 immunization. Our data: (i) confirm the intrathecal antigen-specific plasma cell expansion in LGI1- and CASPR2-AIE in a large cohort of untreated AIE patients; (ii) suggest that activated and expanded central memory CD4 and CD8 T cells in the CSF participate in disease pathogenesis; and (iii) implicate invariant T-cell receptor-expressing lymphocytes in the brain, CSF and blood in disease pathogenesis.
- Open Access
- 6 August 2024
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (9) , 6325-6335
LGI1 encephalitis: potentially complement-activating anti-LGI1-IgG subclasses 1/2/3 are associated with the development of hippocampal sclerosis
Two-thirds of published patients with anti-leucine rich, glioma inactivated 1 (LGI1) encephalitis develop hippocampal sclerosis (HS). It is likely that this contributes to residual cognitive long-term deficits and the risk of epilepsy. Almost all patients harbor anti-LGI1-immunoglobulin G-(IgG-) subclass 4, which is considered a “benign”, non-destructive subclass. In contrast, neuropathological case studies have suggested that the classical complement cascade may contribute to mediotemporal cell death in patients with LGI1 antibodies. IgG subclasses 1, 2, or 3 are required to initiate this cascade. We hypothesized that patients with these anti-LGI1-IgG1/2/3 in addition to IgG4 have a higher risk of developing HS than patients with anti-LGI1-IgG4 alone. We retrospectively assessed all anti-LGI1 encephalitis patients from this center with anti-LGI1-IgG-subclass information and follow-up MRI available. Nine out of 20 patients had developed HS (45%). Volumetric FreeSurfer analysis confirmed the visual HS diagnoses. HS and a lower hippocampal volume were associated with anti-LGI1-IgG1/2/3. All six patients with this IgG subclass status developed HS. There was no association with older or younger age at onset, female sex, longer latency from disease onset to start of immunotherapy, less intense immunotherapy, higher serum titers of LGI1 antibodies, LGI1 antibodies in CSF or higher LGI1-specific antibody indices. There was no association between anti-LGI1-IgG1/2/3 status and neuropsychological performance, epilepsy, or general neurological performance. This confirms our hypothesis that anti-LGI1-IgG1/2/3 in serum puts patients at risk of developing HS. If these findings can be confirmed and clinically corroborated, patients with anti-LGI1-IgG1/2/3 might become candidates for anti-complement-directed immunological treatments.
- 6 August 2024
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (9) , 6325-6335
Open AccessLGI1 encephalitis: potentially complement-activating anti-LGI1-IgG subclasses 1/2/3 are associated with the development of hippocampal sclerosis
Two-thirds of published patients with anti-leucine rich, glioma inactivated 1 (LGI1) encephalitis develop hippocampal sclerosis (HS). It is likely that this contributes to residual cognitive long-term deficits and the risk of epilepsy. Almost all patients harbor anti-LGI1-immunoglobulin G-(IgG-) subclass 4, which is considered a “benign”, non-destructive subclass. In contrast, neuropathological case studies have suggested that the classical complement cascade may contribute to mediotemporal cell death in patients with LGI1 antibodies. IgG subclasses 1, 2, or 3 are required to initiate this cascade. We hypothesized that patients with these anti-LGI1-IgG1/2/3 in addition to IgG4 have a higher risk of developing HS than patients with anti-LGI1-IgG4 alone. We retrospectively assessed all anti-LGI1 encephalitis patients from this center with anti-LGI1-IgG-subclass information and follow-up MRI available. Nine out of 20 patients had developed HS (45%). Volumetric FreeSurfer analysis confirmed the visual HS diagnoses. HS and a lower hippocampal volume were associated with anti-LGI1-IgG1/2/3. All six patients with this IgG subclass status developed HS. There was no association with older or younger age at onset, female sex, longer latency from disease onset to start of immunotherapy, less intense immunotherapy, higher serum titers of LGI1 antibodies, LGI1 antibodies in CSF or higher LGI1-specific antibody indices. There was no association between anti-LGI1-IgG1/2/3 status and neuropsychological performance, epilepsy, or general neurological performance. This confirms our hypothesis that anti-LGI1-IgG1/2/3 in serum puts patients at risk of developing HS. If these findings can be confirmed and clinically corroborated, patients with anti-LGI1-IgG1/2/3 might become candidates for anti-complement-directed immunological treatments.
- Open Access
- 12 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
CHIT1 at diagnosis predicts faster disability progression and reflects early microglial activation in multiple sclerosis
Multiple sclerosis (MS) is characterized by heterogeneity in disease course and prediction of long-term outcome remains a major challenge. Here, we investigate five myeloid markers – CHIT1, CHI3L1, sTREM2, GPNMB and CCL18 – in the cerebrospinal fluid (CSF) at diagnostic lumbar puncture in a longitudinal cohort of 192 MS patients. Through mixed-effects and machine learning models, we show that CHIT1 is a robust predictor for faster disability progression. Integrative analysis of 11 CSF and 26 central nervous system (CNS) parenchyma single-cell/nucleus RNA sequencing samples reveals CHIT1 to be predominantly expressed by microglia located in active MS lesions and enriched for lipid metabolism pathways. Furthermore, we find CHIT1 expression to accompany the transition from a homeostatic towards a more activated, MS-associated cell state in microglia. Neuropathological evaluation in post-mortem tissue from 12 MS patients confirms CHIT1 production by lipid-laden phagocytes in actively demyelinating lesions, already in early disease stages. Altogether, we provide a rationale for CHIT1 as an early biomarker for faster disability progression in MS.
- 12 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Open AccessCHIT1 at diagnosis predicts faster disability progression and reflects early microglial activation in multiple sclerosis
Multiple sclerosis (MS) is characterized by heterogeneity in disease course and prediction of long-term outcome remains a major challenge. Here, we investigate five myeloid markers – CHIT1, CHI3L1, sTREM2, GPNMB and CCL18 – in the cerebrospinal fluid (CSF) at diagnostic lumbar puncture in a longitudinal cohort of 192 MS patients. Through mixed-effects and machine learning models, we show that CHIT1 is a robust predictor for faster disability progression. Integrative analysis of 11 CSF and 26 central nervous system (CNS) parenchyma single-cell/nucleus RNA sequencing samples reveals CHIT1 to be predominantly expressed by microglia located in active MS lesions and enriched for lipid metabolism pathways. Furthermore, we find CHIT1 expression to accompany the transition from a homeostatic towards a more activated, MS-associated cell state in microglia. Neuropathological evaluation in post-mortem tissue from 12 MS patients confirms CHIT1 production by lipid-laden phagocytes in actively demyelinating lesions, already in early disease stages. Altogether, we provide a rationale for CHIT1 as an early biomarker for faster disability progression in MS.
- Open Access
- 9 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (23) , eabq7595
Translational imaging of TSPO reveals pronounced innate inflammation in human and murine CD8 T cell–mediated limbic encephalitis
Autoimmune limbic encephalitis (ALE) presents with new-onset mesial temporal lobe seizures, progressive memory disturbance, and other behavioral and cognitive changes. CD8 T cells are considered to play a key role in those cases where autoantibodies (ABs) target intracellular antigens or no ABs were found. Assessment of such patients presents a clinical challenge, and novel noninvasive imaging biomarkers are urgently needed. Here, we demonstrate that visualization of the translocator protein (TSPO) with [ 18 F]DPA-714-PET-MRI reveals pronounced microglia activation and reactive gliosis in the hippocampus and amygdala of patients suspected with CD8 T cell ALE, which correlates with FLAIR-MRI and EEG alterations. Back-translation into a preclinical mouse model of neuronal antigen-specific CD8 T cell–mediated ALE allowed us to corroborate our preliminary clinical findings. These translational data underline the potential of [ 18 F]DPA-714-PET-MRI as a clinical molecular imaging method for the direct assessment of innate immunity in CD8 T cell–mediated ALE.
- 9 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (23) , eabq7595
Open AccessTranslational imaging of TSPO reveals pronounced innate inflammation in human and murine CD8 T cell–mediated limbic encephalitis
Autoimmune limbic encephalitis (ALE) presents with new-onset mesial temporal lobe seizures, progressive memory disturbance, and other behavioral and cognitive changes. CD8 T cells are considered to play a key role in those cases where autoantibodies (ABs) target intracellular antigens or no ABs were found. Assessment of such patients presents a clinical challenge, and novel noninvasive imaging biomarkers are urgently needed. Here, we demonstrate that visualization of the translocator protein (TSPO) with [ 18 F]DPA-714-PET-MRI reveals pronounced microglia activation and reactive gliosis in the hippocampus and amygdala of patients suspected with CD8 T cell ALE, which correlates with FLAIR-MRI and EEG alterations. Back-translation into a preclinical mouse model of neuronal antigen-specific CD8 T cell–mediated ALE allowed us to corroborate our preliminary clinical findings. These translational data underline the potential of [ 18 F]DPA-714-PET-MRI as a clinical molecular imaging method for the direct assessment of innate immunity in CD8 T cell–mediated ALE.
- Open Access
- 3 May 2023
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 20 (1) , 1-13
Sequential treatment with a TNFR2 agonist and a TNFR1 antagonist improves outcomes in a humanized mouse model for MS
TNF signaling is an essential regulator of cellular homeostasis. Through its two receptors TNFR1 and TNFR2, soluble versus membrane-bound TNF enable cell death or survival in a variety of cell types. TNF-TNFRs signaling orchestrates important biological functions such as inflammation, neuronal activity as well as tissue de- and regeneration. TNF-TNFRs signaling is a therapeutic target for neurodegenerative diseases such as multiple sclerosis (MS) and Alzheimer’s disease (AD), but animal and clinical studies yielded conflicting findings. Here, we ask whether a sequential modulation of TNFR1 and TNFR2 signaling is beneficial in experimental autoimmune encephalomyelitis (EAE), an experimental mouse model that recapitulates inflammatory and demyelinating aspects of MS. To this end, human TNFR1 antagonist and TNFR2 agonist were administered peripherally at different stages of disease development in TNFR-humanized mice. We found that stimulating TNFR2 before onset of symptoms leads to improved response to anti-TNFR1 therapeutic treatment. This sequential treatment was more effective in decreasing paralysis symptoms and demyelination, when compared to single treatments. Interestingly, the frequency of the different immune cell subsets is unaffected by TNFR modulation. Nevertheless, treatment with only a TNFR1 antagonist increases T-cell infiltration in the central nervous system (CNS) and B-cell cuffing at the perivascular sites, whereas a TNFR2 agonist promotes Treg CNS accumulation. Our findings highlight the complicated nature of TNF signaling which requires a timely balance of selective activation and inhibition of TNFRs in order to exert therapeutic effects in the context of CNS autoimmunity.
- 3 May 2023
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 20 (1) , 1-13
Open AccessSequential treatment with a TNFR2 agonist and a TNFR1 antagonist improves outcomes in a humanized mouse model for MS
TNF signaling is an essential regulator of cellular homeostasis. Through its two receptors TNFR1 and TNFR2, soluble versus membrane-bound TNF enable cell death or survival in a variety of cell types. TNF-TNFRs signaling orchestrates important biological functions such as inflammation, neuronal activity as well as tissue de- and regeneration. TNF-TNFRs signaling is a therapeutic target for neurodegenerative diseases such as multiple sclerosis (MS) and Alzheimer’s disease (AD), but animal and clinical studies yielded conflicting findings. Here, we ask whether a sequential modulation of TNFR1 and TNFR2 signaling is beneficial in experimental autoimmune encephalomyelitis (EAE), an experimental mouse model that recapitulates inflammatory and demyelinating aspects of MS. To this end, human TNFR1 antagonist and TNFR2 agonist were administered peripherally at different stages of disease development in TNFR-humanized mice. We found that stimulating TNFR2 before onset of symptoms leads to improved response to anti-TNFR1 therapeutic treatment. This sequential treatment was more effective in decreasing paralysis symptoms and demyelination, when compared to single treatments. Interestingly, the frequency of the different immune cell subsets is unaffected by TNFR modulation. Nevertheless, treatment with only a TNFR1 antagonist increases T-cell infiltration in the central nervous system (CNS) and B-cell cuffing at the perivascular sites, whereas a TNFR2 agonist promotes Treg CNS accumulation. Our findings highlight the complicated nature of TNF signaling which requires a timely balance of selective activation and inhibition of TNFRs in order to exert therapeutic effects in the context of CNS autoimmunity.